18Apr 2025
Ponatinib Improves Quality of Life in Ph+ ALL Patients

Ponatinib Improves Quality of Life in Ph+ ALL Patients

In the Phase 3 PhALLCON trial, ponatinib showed superior patient-reported outcomes (PROs) compared to imatinib in newly diagnosed Ph+ acute lymphoblastic leukemia. Using FACT-Leu and EQ-5D-5L tools, significant improvements were noted in key domains including physical well-being and treatment tolerability. Ponatinib led to faster symptom improvement and less bother from side effects, reinforcing its role as a preferred frontline option in Ph+ ALL.

  • #oncology

Like

Save

Share